Related references
Note: Only part of the references are listed.Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
Marie-Anne Hospital et al.
BLOOD (2014)
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center
Ya-Zhen Qin et al.
LEUKEMIA RESEARCH (2014)
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AMLStudy Group (AMLSG)
Peter Paschka et al.
BLOOD (2013)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Hong-Hu Zhu et al.
BLOOD (2013)
Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience
R. Guieze et al.
LEUKEMIA (2010)
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
Yachiyo Kuwatsuka et al.
BLOOD (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease
YaZhen Qin et al.
LEUKEMIA RESEARCH (2009)
Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation
Norbert-Claude Gorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A >= 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse
Steven Lane et al.
LEUKEMIA & LYMPHOMA (2008)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
Frederick R. Appelbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation
DP Lu et al.
BLOOD (2006)
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
G Perea et al.
LEUKEMIA (2006)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies
MM Schittenhelm et al.
CANCER RESEARCH (2006)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
E Beillard et al.
LEUKEMIA (2003)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML):: a survey of 110 cases from the French AML Intergroup
J Delaunay et al.
BLOOD (2003)
Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias
J Krauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts
A Guerrasio et al.
LEUKEMIA (2002)
Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia
G Marcucci et al.
LEUKEMIA (2001)
Share Paper
